IFITM1 has been reported to be abnormally expressed in tumor tissues and it is an independent prognostic biomarker for patients with acute myeloid leukemia (40), lung adenocarcinoma (41) and gallbladder cancer (42). Here, IFITM1 is linked to lung adenocarcinoma.